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Summal'y 
A murine model of peritonitis was used to test the role of platelet/endothelial cell adhesion molecule 
1 (PECAM-1/CD31) in acute inflammation. A monoclonal antibody (mAb) specific for murine 
PECAM-1 injected intravenously 4 h before the intraperitoneal injection of thioglycollate broth 
blocked leukocyte emigration into the peritoneal cavity for up to 48 h. This block was particularly 
evident for neutrophils.  Control mAb, including one that bound to murine CD18 without blocking 
its function, failed to block emigration when used at the same or higher concentrations. The 
decreased  emigration seen with the anti-PECAM-1  antibody was not due to neutropenia or 
neutrophil sequestration in the lung, spleen, or other organs; peripheral blood leukocyte counts 
were not diminished in these mice. In the mesenteric venules of the mice treated with anti- 
PECAM-1 mAb, leukocytes were frequently seen in association with the luminal surface of the 
vessel, but did not appear to emigrate. Thus, the requirement for PECAM-1 in the transendothelial 
migration of leukocytes previously seen in an in vitro model holds true in this in vivo model 
of acute inflammation. 
p latelet/endothelial cell adhesion molecule 1 (PECAM-1/ 
CD31) is a member of the Ig gene superfamily (1) con- 
centrated at the intercellular  junctions of cultured human en- 
dothelial cells  (HEC)  (2)  and expressed  on the surface of 
platelets (1) and most leukocytes. We have demonstrated that 
PECAM-1 is required for the migration of monocytes and 
neutrophils across resting and cytokine-activated HEC in a 
quantitative in vitro assay of transmigration (3). 
Recent characterization of the murine homolog of PECAM-1 
has afforded us the opportunity to test the role of this mole- 
cule in an in vivo model of inflammation. Cloning of the 
routine homolog of PECAM-1 (4) revealed a predicted amino 
acid sequence with 79% homology to human CD31. L cells 
transfected with murine PECAM-1 cDNA aggregated in a 
PECAM-l-dependent manner, similar to human PECAM-1 
transfectants. A mAb raised in hamsters that recognizes the 
murine form of CD31 (5) blocked this aggregation (4). Fur- 
thermore, immunohistochemical studies using this antibody 
demonstrated that murine PECAM-1 had a tissue distribu- 
tion similar to that of human PECAM-1  (5). 
We used a murine model of acute peritonitis to test whether 
intravenously  administered  anti-murine  PECAM-1  mAb 
would block acute inflammation. The results demonstrate 
that anti-PECAM-1 mAb inhibits emigration of neutrophils 
(PMN) to nearly background levels, establishing PECAM-1 
as an important adhesion molecule in the inflammatory re- 
sponse. 
Materials  and Methods 
Animals.  Female  mice of the CD2F1 strain weighing '~20 g 
were purchased from Charles River Laboratories  (Boston, MA) and 
housed at The Rockefeller  University Laboratory Animal Research 
Center. Female mice of the AKR/J strain were purchased from 
The Jackson Laboratory  (Bar Harbor, ME) and housed at the Boston 
University School of Medicine Laboratory Animal Science Center. 
All animal  procedures had been approved  by the Rockefeller  Univer- 
sity and Boston University School of Medicine IACUCs. Animals 
were handled according to guidelines set forth in the "Guide for 
the Care and Use of Laboratory Animals" and the "Animal Wel- 
fare Act." Mice were housed together in standard cages and allowed 
free access to mouse chow and water. 
Monoclonal  Antibodies.  mAb  2H8  hamster  anti-murine 
PECAM-1 was produced as described (5) and purified by HPLC 
using a semi-preparative column (ABx; J. T. Baker, Inc., Phillips- 
burg, NJ), loading in 25 mM 2-[N-Morpholino]ethanesulfonic  acid 
(MES), pH 5.7, and eluting with a linear 10-60% gradient of 500 
mM NH4SO4 plus 5 mM KH2PO4, pH 6.7, according to the 
manufacturer's recommendations. Purification of the 2H8 mAb 
under denaturing conditions resulted in an antibody preparation 
that was less effective  in vivo. The 2H8 mAb was negative for en- 
dotoxin by the Limulus amebocyte lysate assay (Sigma Chemical 
Co., St. Louis, MO). The hamster anti-murine CD18 mAb 2E6 
was originally raised at The Rockefeller University (6) and was 
donated  by  Endogen,  Inc. (Boston, MA).  Hybridoma  lines 
producing mAb 5C6 (rat anti-routine CDllb) (7) were generously 
provided by Dr.  Hugh  Rosen  (Merck Research Laboratories, 
Rahway, NJ). IgG was purified from cell supernatant as previously 
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ImmunoResearch Laboratories,  Inc.  (West Grove, PA). All mAb 
were documented to recognize their specific antigens by flow cytom- 
etry and/or immunohistochemistry. 
Immunohistochemistry.  Leukocytes were isolated from buffy coats 
of blood collected by cardiac puncture in heparinized syringes. RBC 
were lysed by resuspension of the buffy  coat pellet in 9 vol of 
pyrogen-free distilled water for 60 s on ice. I vol of 10 X PBS was 
added,  the suspension  was centrifuged, and the pellet containing 
leukocytes was washed in HBSS. Frozen sections of mouse tissue, 
or cytospin preparations of isolated PBL or peritoneal exudate cells, 
were stained by indirect immunoperoxidase histochemistry as pre- 
viously described (2,  5). Briefly, endogenous peroxidase activity 
was quenched by reaction with H202, the sections were incubated 
with primary mAb diluted in PBS/OVA for 30 min at room tem- 
perature, washed in PBS/OVA, then incubated in a 1:200 dilution 
of horseradish  peroxidase-conjugated  rabbit  anti-hamster  IgG 
(Accurate Scientific  Corp.,  Westbury, NY) for 30 rain at room 
temperature before washing and developing with diaminobenzi- 
dine-H202. 
Experimental Procedure.  The emigration of PMN into the mouse 
peritoneal cavity in response to intraperitoneal injection of thiogly- 
collate broth is a well-established  model of acute inflammation (8, 
9). Mice were injected intravenously via the lateral tail vein with 
the various mAb diluted in Dulbecco's PBS (DPBS) to a final volume 
of '-100 r  Some control mice received DPBS alone or an equiva- 
lent dose of normal hamster IgG. 4 h later, mice were injected in- 
traperitoneally with 1 ml of 4% Brewer's thioglycollate broth (Difco, 
Detroit, MI). 24 h after the mAb injection, mice were killed by 
exposure to CO2. Peritoneal cells were recovered into tubes on ice 
by lavage with 5 ml of divalent cation-free HBSS (GIBCO BRL, 
Gaithersburg, MD) using standard techniques (10). Heparinized 
blood was collected by cardiac puncture or from the retro-orbital 
sinus. Peritoneal cell counts and peripheral white blood cell counts 
were performed employing erythrocyte lysis kits (Unopette; Fisher 
Scientific,  Pittsburgh,  PA) on samples from each mouse using a 
hemacytometer. Differential counts were performed on Wright/ 
Giemsa-stained cytospin preparations (for peritoneal ceils) and pe- 
ripheral blood smears. 
The abdominal and thoracic cavities were inspected for signs 
of gross pathology. The mesenteric LN were harvested and fixed 
in 4% paraformaldehyde, 2% glutaraldehyde in 0.1 M sodium phos- 
phate buffer, pH 7.4. The liver and spleen were excised intact and 
weighed. These organs,  along with the majority of the small and 
large bowel, were fixed in neutral buffered formalin. Representa- 
tive regions were embedded in paraflfin or methyl methacrylate. 
Sections  were cut and stained  with hematoxylin and eosin. 
Results and Discussion 
mAb  against Murine  PECAM-I  Blocks  Acute  Inflamma- 
tion.  To test whether PECAM-1 plays a critical role for acute 
inflammation in vivo, we administered the hamster anti-mu- 
rine PECAM-1 mAb 2H8 (5), or appropriate positive or nega- 
tive control mAb, intravenously, 4 h before the intraperitoneal 
injection of thioglycollate broth (Fig.  1).  In this well-esta- 
blished model of acute peritonitis, intraperitoneal thioglycollate 
induces  an influx of neutrophils  into  the peritoneal cavity 
within the first 2 h  (8, 9). The degree of inflammation was 
measured by peritoneal lavage 20 h after thioglycollate injec- 
tion. In seven out of seven experiments performed, the anti- 
PECAM-1 mAb prevented the emigration ofleukocytes into 
the  peritoneal  cavity.  Two  representative  experiments  are 
shown in Fig.  1.  In all cases,  the effect of anti-PECAM-1 
mAb was comparable with that of the positive control mAb 
5C6 (anti-CDllb), which had previously been shown to block 
acute  inflammation  in  this  model  (7).  Production  and 
purification of active Fab or F(ab')2 fragments of 2H8 proved 
technically problematic. Therefore, in experiment 2 and other 
similar experiments, a hamster anti-mouse CD18 (2E6) served 
as a control, since it binds tightly to murine leukocytes, but 
is a relatively weak blocker ofintegrin function (6). The failure 
of this mAb  to block emigration rules  against  nonspecific 
or Fc-mediated effects of bound mAb being responsible for 
the block seen with anti-PECAM-1  mAb. Immunostaining 
of peripheral blood from mice treated with 2E6 demonstrated 
that leukocytes still bound readily detectable levels of this mAb 
at  the  time of killing  (data  not  shown). 
Fig.  1 separately reports data on the PMN  exudate and 
the total exudate cells  (including  lymphocytes and  macro- 
phages).  The decrease in PMN  accumulation  produced by 
the anti-PECAM-1 mAb is particularly dramatic, since these 
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Figure  1.  Anti-PECAM-1 mAb blocks 
leukocyte  emigration  in response to thiogly- 
collate injection. Peritoneal  cells were har- 
vested at 24 h from mice that had received 
250 #g of the indicated  mAb, normal ham- 
ster IgG (N. Ham. IgG), or DPBS (None), 
intravenously, at time zero and thioglycol- 
late or DPBS intraperitoneally  at 4 h. Two 
experiments, representative of seven, are 
shown. AKR/J mice were used in experi- 
ment  1;  CD2F1 mice in experiment 2. 
Bars indicate mean _+ SEM for each group 
(five mice per group). cells are not normally resident in the peritoneal cavity. Addi- 
tional experiments (not shown) revealed that significant sup- 
pression of inflammation by mAb 2H8 was achieved at doses 
as low as 50/~g/mouse (the lowest dose tested), and suppres- 
sion was maintained for at least 48 h. This time course is 
similar to that described with anti-CD11b blockade (7) and 
significantly longer than the 4-h suppression seen in this model 
by blockade of L-selectin (9), or knockout of P-selectin  (11). 
Anti-PECAM-I  mAb Appears  to Arrest Emigration  of Ad- 
herent Leukocytes.  Administration of these antibodies did not 
lower the circulating leukocyte count. In fact, at the time 
of killing, there was a granulocytosis in those mice that had 
received anti-PECAM-1 mAb (Table 1), consistent with the 
hypothesis that PMN were being recruited into the circula- 
tion, but blocked from emigrating to the site of inflamma- 
tion. Histologic examination revealed no abnormal accumu- 
lations of leukocytes in the spleens or livers (data not shown). 
Absolute platelet counts were not performed, but no differ- 
ence in platelet numbers or appearance  on peripheral blood 
smears  was seen among the experimental groups. 
Histologic examination of the  mesenteries of the mice 
receiving anti-PECAM-1 mAb showed increased numbers of 
intravascular  PMN in the venules compared with controls. 
These PMN appeared  to be in contact with the endothelial 
surface (Fig.  2),  but were inhibited from migrating across 
the vascular wall, analogous to the block of transmigration 
observed in vitro (3). Fig. 2 a shows one of the more extreme 
examples of this phenomenon encountered; however, about 
60% of random mesenteric venular profiles in anti-PECAM- 
1-treated mice appeared  to bear adherent leukocytes (Fig. 2 
e). This phenomenon was seen in postcapillary venules,  as 
well as in slightly larger venules, which are also sites of emigra- 
tion of PMN (12). Since the chances of finding a truly nonad- 
herent leukocyte adjacent to the endothelium were less in 
these larger diameter venules,  10 random sections of such 
venules (50-150 #m diameter) were examined on coded slides 
from each mouse, and leukocytes in contact with the vessel 
wall or free in circulation were counted. Only rare leuko- 
cytes contacted the endothelium in control (no thioglycol- 
late)  animals  or in animals receiving mAb other than 2H8 
(Fig. 2, b and e). There was variability among venules, but 
overall, 34% of all leukocytes seen in the venules of the anti- 
PECAM-l-treated mice were in apparent contact with the 
endothelium. Immunohistologic examination of these mice 
demonstrated that anti-PECAM-1 mAb was still specifically 
retained by endothelium in vascular  structures,  including 
mesenteric venules. Since these vessels are found in fatty tissue 
and therefore are cut poorly by frozen section, this pheno- 
menon is demonstrated on vessels within the bowel wall (Fig. 
2, c and d). Residual 2H8 on circulating PMN could not be 
detected using immunoperoxidase techniques.  However, this 
could be due to turnover of PMN during the 24 h and/or 
shedding of murine PECAM-1  from PMN membranes. 
Anti-PECAM-I  mAb  Blocks  Emigration  of Mononuclear 
Cells.  Significant numbers of mononuclear cells as well as 
PMN  are recruited to  the peritoneal cavity by 20  h  after 
thioglycollate injection. Fig. I demonstrates that the increase 
in peritoneal exudate cells is not accounted for by the increase 
in PMN alone. Anti-PECAM-1 mAb 2H8 also blocked the 
influx of mononuclear cells into the peritoneum (Fig. 1, right). 
To determine if PECAM-1 blockade affected mononuclear 
cell trafficking, we examined the mesenteric LN draining the 
peritoneal cavity. The peritoneal cavity is drained by, among 
other lymphatic beds, the mesenteric plexus. Peritoneal mono- 
nuclear cells in the afferent lymphatics would enter draining 
LN via the subcapsular sinus. Examination of mesenteric nodes 
revealed large numbers of mononuclear cells entering via the 
subcapsular sinus in mice stimulated with thioglycollate, but 
relatively few in the subcapsular  sinuses of mice given anti- 
PECAM-1 mAb before thioglycollate (Fig. 3). The paucity 
Table  1.  Pe@heral Blood Leukocyte Counts for Experiment in Fig. I 
Thioglycollate  Antibody  White blood cells (cells/#l)  Differential (P/L/M) 
Experiment 1 (AKR/J strain) 
Experiment 2 (CD2F1 strain) 
+  Normal hamster IgG  4,438  _+  169"  36/59/5* 
-  None  4,963  +  699  19/75/6 
+  Anti-PECAM (2H8)  4,548  +  242  62/35/3 
+  Anti-CD11b  (5C6)  2,838  _+  234  20/65/15 
+  Anti-CD18  (2E6)  9,640  _+  1,270  28/65/7 
-  None  12,260  _+  1,970  11/77/12 
+  Anti-PECAM  (2H8)  16,060  _+ 2,750  59/33/8 
+  Anti-CDllb (5C6)  11,580  _+  3,460  20/74/6 
* Peripheral white blood cell count. Data expressed as mean +_ standard error of mean. 
Percentages of polymorphonuclear  leukocytes  (neutrophils)/lymphocytes/monocytes from t>100 cells counted. Note that a normal mouse white 
blood cell differential  count is dominated  by lymphocytes.  Mice receiving thioglycollate  displayed  increased  percentages of myeloid  forms, including 
immature forms, which are grouped with the neutrophils. 
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tion of the block of mononuclear cell entry into the perito- 
neal cavity. These data are in agreement with those of Fig. 
1, and selectively represent  the mononuclear cell fraction.  PMN 
do not recirculate into the draining lymphatics in general and 
were not seen in the subcapsular sinuses of the LN of these 
mice. 
Furthermore,  in  some  experiments,  the  thioglycollate- 
elicited  peritoneal  exudate  cell  count  was  lower  for  anti- 
PECAM-l-treated mice than for control mice not stimulated 
with  thioglycollate  (Fig.  1,  right).  This  suggested  that 
PECAM-1  may be required for the constitutive  trafficking 
of mononuclear cells through the peritoneum,  as well as for 
the  thioglycollate-elicited  emigration. 
In an in vitro model using human leukocytes and endothelial 
cells, anti-PECAM-1 mAb or soluble recombinant PECAM-1 
did  not  affect  attachment,  but  blocked  transmigration  of 
monocytes and PMN (3), which remained tightly adherent 
to the apical surface over the intercellular junctions,  the site 
at which endothelial PECAM-1 is concentrated (2). The func- 
tion of PECAM-1  in transendothelial  migration  was distal 
to  the  selectin-mediated  rolling  and  the  /~2  integrin-me- 
diated tight adhesion to the apical  surface of the venular en- 
dothelium. The results of the present study (Fig.  2) suggest 
that PECAM-1 plays a similar role in vivo, since leukocytes 
blocked from entering the peritoneal cavity by anti-PECAM-1 
mAb were apparently arrested on the luminal surface of the 
venular endothelium.  We presume that the arrest on the en- 
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Figure  2.  Mesenteric  venules from anti-PECAM-l-treated mice show 
increased numbers ofintraluminal leukocytes  in apparent contact with the 
endothelium. Mice treated with anti-PECAM-1  mAb as in Fig. 1 revealed 
a high proportion  of  leukocytes  (predominantly  PMN, arrowheads)  in random 
sections in contact with the endothelium (a), whereas mice treated with 
the nonblocking  anti-CD18 mAb showed  rare leukocytes  on the endothelial 
surface (b), despite the fact that many had transmigrated. Immunoperoxi- 
dase staining of  frozen sections ofmesenteric tissue demonstrated that the 
anti-PECAM-1 mAb injected 24 h previously was still localized to en- 
dothelial ceils in vascular structures (arrow, c), whereas anti-CD18 mAb 
(d) stained only occasional  stellate cells adjacent to the crypts (arrowheads) 
and lamina propria (not shown) of  the bowel, but not blood vessels (arrow). 
Quantitation of over 400 leukocytes  in 10 random venular profiles from 
each of the five  mice per group revealed  that only the anti-PECAM-1  mAb 
group had significant numbers of leukocytes remaining in contact with 
the endothelium (e). Data are expressed as the percent total intravascular 
leukocytes apparently in contact with the venular wall (open bars) and as 
the number of profiles counted (out of 10 per mouse) that bore more than 
one adherent leukocyte. These data are converted to a percentage. The 
mean  _+  SD for groups of five mice is shown. (a and b)  x415; (c and 
d)  x 260. Arrows in (a) and (b) point to endothelial nuclei. (L) Venular 
lumen; (S) small bowel serosal surface; (C) intestinal crypts. 
dothelial  surface is transient,  since the vast majority of the 
luminal surface of the affected venules was free of leukocytes, 
and the granulocytosis was persistent.  The block of emigra- 
tion effected by anti-PECAM-1  mAb appears  to involve a 
different mechanism than the block by anti-CDllb.  In the 
latter case, no granulocytosis was seen in the peripheral blood, 
and, although PMN emigration into the peritoneum was in- 
hibited,  leukocytes were not seen in apparent contact with 
Figure 3.  Relative  paucity ofmononuclear cells in the subcapsular  sinus 
of the draining mesenteric nodes in anti-PECAM-l-treated mice. Mesen- 
teric LN from thioglycolate-treated  mice were fixed and sectioned as de- 
scribed in Materials and Methods. (a) The subcapsular sinus (asterisk, ver- 
tical lines define  width of sinus) of a representative node from mice treated 
with normal hamster IgG. Note the large numbers of mononuclear cells 
within the sinus, indicating their recent arrival via afferent lymphatics. 
(b) The relative  few mononuclear  cells in the same  area from a mouse  treated 
with 2H8 anti-PECAM-1, correlating with the decreased total peritoneal 
cells recovered from peritoneal lavage. ￿ 
the venular wall.  This  is consistent with the proposed role 
of/32 integrins  in mediating  the  tight  adhesion  to the en- 
dothelial  surface (13-15). 
In our in vitro model, leukocyte transmigration could be 
blocked equally well by treating either the leukocytes or the 
endothelial  cells with anti-PECAM-1 reagents.  We do not 
know whether  the 2H8  mAb is blocking leukocyte trans- 
migration by blocking PECAM-1 on leukocytes, endothelium, 
or both. 
Since anti-PECAM-1 mAb blocked emigration of mono- 
nuclear cells as well as PMN in vivo, PECAM-1 may mediate 
a function common to all leukocyte types that  is necessary 
for the process  of transendothelial  migration.  In addition, 
the inhibition was effected at a low dose of anti-PECAM-1 
mAb (50/zg/mouse  in  certain  experiments)  and lasted  up 
to 48 h  after a single injection.  These observations suggest 
that PECAM-1 may be a suitable molecule to target in anti- 
inflammatory therapy. 
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Note Added in Proof: Vaporciyan et al. have recently reported experiments in which a rabbit anti-human 
PECAM-1 polyclonal antibody that cross-reacts  with rat PECAM inhibited emigration of PMN for 4 h 
in three rat models of acute inflammation (16). 
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